Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

How New Models Of Vaccine Development For COVID-19 Have Helped Address An Epic Public Health Crisis.

Tytuł:
How New Models Of Vaccine Development For COVID-19 Have Helped Address An Epic Public Health Crisis.
Autorzy:
Bloom DE; David E. Bloom () is a professor in the Department of Global Health and Population at the Harvard T. H. Chan School of Public Health, in Boston, Massachusetts.
Cadarette D; Daniel Cadarette is a research and communications manager in the Department of Global Health and Population at the Harvard T. H. Chan School of Public Health.
Ferranna M; Maddalena Ferranna is a research associate in the Department of Global Health and Population at the Harvard T. H. Chan School of Public Health.
Hyer RN; Randall N. Hyer was vice president of clinical development and medical affairs at Dynavax, in Emeryville, California, at the time of this writing. He is now senior vice president, Global Medical Affairs, at Moderna in Cambridge, Massachusetts.
Tortorice DL; Daniel L. Tortorice is an assistant professor of economics and accounting at College of the Holy Cross, in Worcester, Massachusetts.
Źródło:
Health affairs (Project Hope) [Health Aff (Millwood)] 2021 Mar; Vol. 40 (3), pp. 410-418. Date of Electronic Publication: 2021 Feb 04.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Publication: : Bethesda, MD : Project Hope
Original Publication: Millwood, Va. : Project Hope, c1981-
MeSH Terms:
Public Health*
Public-Private Sector Partnerships*
Biomedical Research/*economics
COVID-19 Vaccines/*economics
Drug Development/*economics
COVID-19 ; Humans
Substance Nomenclature:
0 (COVID-19 Vaccines)
Entry Date(s):
Date Created: 20210204 Date Completed: 20210312 Latest Revision: 20210312
Update Code:
20240105
DOI:
10.1377/hlthaff.2020.02012
PMID:
33539191
Czasopismo naukowe
Coronavirus disease 2019 (COVID-19) vaccine development and manufacturing have proceeded at a historically unprecedented pace. This speed may be accounted for by the unprecedented scale of resources being devoted to addressing COVID-19; an unusual intensity of cooperation, encompassing the public and private sectors and occurring both within and across national borders; and innovation with respect to both technologies (for example, new vaccine platforms) and processes (for example, vaccine clinical trials). In this article we describe and analyze how resources, cooperation, and innovation have contributed to the accelerated development of COVID-19 vaccines. Similar levels and types of public investment, models of cooperation, and harnessing of innovative processes and technologies could be applied to future epidemics and other global health challenges.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies